Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12160901 | 1.00 | MEN1 (0.50) | MEN1MAPK1KMT2ANAMPTMAPT | |
| SCHEMBL486204 | 0.86 | MAPT (0.49) | MEN1MAPK1KMT2AMAPTGAA | |
| SCHEMBL12160730 | 0.84 | L3MBTL1 (0.47) | MEN1MAPK1KMT2ANAMPTMAPT | |
| SCHEMBL12160900 | 0.84 | L3MBTL1 (0.47) | MEN1MAPK1KMT2ANAMPTMAPT | |
| SCHEMBL14959009 | 0.82 | DPP4 (0.44) | MEN1MAPK1KMT2ANAMPTMAPT | |
| SCHEMBL31722815 | 0.81 | ALDH1A1 (0.60) | MAPK1GAAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL24725070 | 0.81 | NPC1 (0.48) | KMT2ANAMPTMAPTGAAALDH1A1 | |
| SCHEMBL26878431 | 0.79 | LMNA (0.48) | MEN1MAPK1KMT2ANAMPTMAPT | |
| SCHEMBL25083897 | 0.79 | LMNA (0.48) | MEN1MAPK1KMT2ANAMPTMAPT | |
| SCHEMBL26899136 | 0.79 | NPC1 (0.46) | MEN1KMT2ANAMPTMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779576-B2 | Method of treating C3 glomerulopathy | CHEMOCENTRYX, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20180179160-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9126939-B2 | C5AR antagonists | CHEMOCENTRYX, INC. | 2015-09-08 | — | — | US | disclosed |
| US-20150141425-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20110275639-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141425-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885MAPK1 3645/4885KMT2A 4442/4885 |
| US-20110275639-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885MAPK1 3645/4885KMT2A 4442/4885 |
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885MAPK1 3645/4885KMT2A 4442/4885 |
| US-20180179160-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885MAPK1 3645/4885KMT2A 4442/4885 |
| US-11779576-B2 | Method of treating C3 glomerulopathy | C3AR1, C5, C5AR1 | MEN1 1614/4885MAPK1 4758/4885KMT2A 4638/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885MAPK1 3645/4885KMT2A 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.